JUPITER, Fla., March 14, 2018 /PRNewswire/ — Jupiter Orphan Therapeutics, Inc. (“JOT”), Jupiter, FL, today announced that it had submitted its IND to the FDA on March 12, 2018 for Mucopolysaccharidosis Type-I (MPSI). This will be the first of several anticipated IND submissions in 2018…